Thomas J. Styslinger, Ph.D.
Dr. Thomas Styslinger is a member of the firm’s Intellectual Property practice and a registered patent attorney. His practice focuses on strategic patent counseling, prosecution, and portfolio development advice, including patent opinions and freedom-to-operate analyses. His clients range from start-up and emerging companies to global chemical companies. He has extensive experience in the areas of polymer chemistry, formulation chemistry, material science, adhesives, small-molecule pharmaceuticals, drug delivery technologies, and diagnostics. Dr. Styslinger also has transactional experience in various aspects of IP licensing.
Thomas holds a Ph.D. in chemistry with a focus on organic chemistry, as well as bachelors degrees in chemistry and biological sciences. Thomas has conducted research in the areas of polymer chemistry, biopharmaceuticals, small molecule biosynthesis, natural product synthesis, carbohydrate chemistry, and nanoparticles.
Dr. Styslinger’s scholarly contributions span over eight years of undergraduate and graduate research, and are published in leading academic journals including the Journal of the American Chemical Society. Some of his efforts resulted in new synthetic routes in polymer chemistry as well as alternatives to polyethylene glycol for the protection of biopharmaceuticals.
- Co-author, “Site-Selective Glycosylation of Hemoglobin with Variable Molecular Weight Oligosaccharides: Potential Alternative to PEGylation,” Journal of the American Chemical Society, 2012
- Co-author, “Synthesis of Rare Sugars with L-fuculose-1-phosphate Aldolase (FucA) from Thermus Thermophilus HB8,” Bioorganic & Medicinal Chemistry Letters, 2011
- Co-author, “L-Rhamnose Antigen: A Promising Alternative to α-Gal for Cancer Immunotherapies,” ACS Chemical Biology, 2011
- Co-author, “Characterization of WbiQ: an α1,2-Fucosyltransferase from Escherichia coli O127:K63(B8), and synthesis of H-Type 3 Blood Group Antigen,” Biochemical and Biophysical Research Communications, 2010
- Co-presenter, “Chemoselective glycosylation of hemoglobin as a potential oxygen therapeutic,” American Chemical Society National Meeting, Boston, 2010
- Co-presenter, “An efficient route to construct multivalent carbohydrate based dendrimers,” American Chemical Society Southeast Regional Meeting, Research Triangle Park, North Carolina, 2004
- Selected as a 2017 participant in the Dayton Bar Association’s Leadership Development Program